9thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE:

An Intensive Course on Translating Research into Drugs


Presented by the Alzheimer's Drug Discovery Foundation

March 1-3, 2015  ●  San Diego, CA 

PROGRAM

All sessions will be held at the Westgate Hotel San Diego, Versailles Ballroom, 2nd Floor. Review directions to venue here.

Sunday, March 1, 2015
2:00 pm – 4:00 Registration — Foyer (2nd Floor)
4:00 – 4:20 Welcome & Opening Remarks: Challenges and Opportunities in Academic Drug Discovery
Howard Fillit, MD
— Alzheimer's Drug Discovery Foundation  
4:20 – 5:05 Plenary – A Systems Biology Approach to Understanding Neurodegenerative Disease
Leroy Hood, MD, PhD
— Institute for Systems Biology 
5:05 – 5:15 Q&A
5:15 – 7:00 Welcoming Reception — Riviera Terrace (3rd Floor)
Monday, March 2, 2015
7:00am – 7:00pm Registration — Foyer (2nd Floor)
7:30 – 8:40 Continental Breakfast — Riviera Terrace (3rd Floor)
8:40 – 8:50 Welcome & Opening Remarks
Howard Fillit, MD,
Alzheimer's Drug Discovery Foundation
8:50 – 9:05

NINDS Opportunities for Translational Research Funding 

Mary Ann Pelleymounter, PhD — National Institute of Neurological Disorders and Stroke

I. Embarking on a Drug Discovery Campaign
Chair: Julie Frearson, PhD — Charles River Laboratories
9:05 – 9:10 Session Overview
Julie Frearson, PhD
— Charles River Laboratories 
9:10 – 9:30 Assembling the Right Interdisciplinary Team from the Beginning
Julie Frearson, PhD
— Charles River Laboratories
9:30 – 9:40 Q&A
9:40 – 10:00 Improving Clinical Success through Translational Science for Optimal Target Validation and Biomarkers
Kalpana Merchant, PhD
— TransThera Consulting Co. 
10:00 – 10:10 Q&A
10:10 – 10:30 Considerations and LImitations for Assay Development
William Janzen
— Epizyme
10:30 – 10:40 Q&A
10:40 – 11:00 Exhibitor Session and Break
II. Hit Selection and Lead Optimization
Chair: D. Martin Watterson, PhD — Northwestern University
11:00 – 11:05

Session Overview

D. Martin Watterson, PhD — Northwestern University

11:05 – 11:25

From HTS through Hit Identification and Evaluation: Considerations and Best Practices
Thomas Chung, PhD
— Sanford-Burnham Medical Research Institute

11:25 – 11:35 Q&A
11:35 – 11:55 Learning from Precedents: Project Flow in Early Stage Small Molecule Refinement for CNS Drug Discovery
D. Martin Watterson, PhD
— Northwestern University 
11:55 – 12:05 Q&A
12:05 – 12:25 PK/PD in Preclinical Development
Barry Greenberg, PhD
— University Health Network
12:25 – 12:35 Q&A
12:35 – 1:40 Lunch and Poster Session (All Poster Presenters Should Stand by their Posters from 1:05 to 1:40pm)
III. Drug Discovery: From Lead to Clinical Candidate
Chair: Edward Spack, PhD—Fast Forward, LLC
1:40 – 1:45

Session Overview

Edward Spack, PhD — Fast Forward, LLC

1:45 – 2:05

Lead to Clinical Candidate: Essential Chemical Development Practices

Bruce Molino, PhD — Albany Molecular Research Inc. (AMRI) 

2:05 – 2:15 Q&A
2:15 – 2:35 Early Phase Drug Product Strategies: What Formulation Strategy is Best for Your Goals?
Bryan Knox — Pharmatek
2:35 – 2:45 Q&A
2:45 – 3:05 Requirement for an IND and Early Considerations
Edward Spack, PhD
Fast Forward, LLC
3:05 – 3:15 Q&A
3:15– 3:55 Exhibitor Session and Break
3:55– 4:15 Virtual R&D Operations - How to work with CROs and Consultants
Tilmann Brotz, PhD
— Achaogen, Inc.
4:15 – 4:25 Q&A
4:25 – 4:40 ADDF ACCESS & Young Investigator Scholarship Awards Presentation and Closing Remarks
Lauren Friedman, PhD
— Alzheimer's Drug Discovery Foundation 
4:40 – 6:00 Partnering Session Riviera Room (3rd Floor)
4:40 – 7:00 Networking Reception — Riviera Terrace (3rd Floor)
Tuesday, March 3, 2015
7:30 am – 8:15 Partnering Session — Riviera Room (3rd Floor)
7:30 – 8:30 Continental Breakfast — Fontainebleau Room (2nd Floor)
8:30 – 8:35 Welcome & Opening Remarks
Diana Shineman, PhD
— Alzheimer's Drug Discovery Foundation
8:35 – 9:05 KEYNOTE: Utilizing hiPSC-derived Differentiated Cells for High-throughput Drug Screening
Anne Bang, PhD
— Sanford-Burnham Medical Research Institute
9:05 - 9:15 Q&A
IV. Strategies for CNS Targets – Case Study Examples
Chair: Marcie Glicksman, PhD—Orig3n
9:15 - 9:20

Session Overview

Marcie Glicksman, PhD — Orig3n

9:20 – 9:40 Case Study: The Identification of Klotho Enhancers
Marcie Glicksman, PhD
— Orig3n
9:40 – 9:50 Q&A
9:50 – 10:10 CP2: Generating New Intellectual Property  
Eugenia Trushina, PhD
— Mayo Clinic
10:10 – 10:20 Q&A
10:20 – 10:40

Meeting Regulatory and Commercialization Challenges in Advancing Agb101 to Slow Progression in Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease

Michela Gallagher, PhD — AgeneBio

10:40 – 10:50 Q&A
10:50 – 11:10 Exhibitor Session and Break
11:10 – 11:30 Generating Proof of Concept for AD Using an Orphan Indication
Brandon Wustman, PhD
— Orphi Therapeutics
11:30 – 11:40 Q&A
11:40 – 12:00 Allopregnanolone: From Laboratory Discovery to Clinical Trial
Roberta Diaz Brinton, PhD
— University of Southern California
12:00 – 12:10 Q&A
12:10 – 1:10 pm Lunch and Poster Session (All Poster Presenters Should Stand by their Posters from 12:40 to 1:10 pm)
V. Developing Science into Products
Chair: Frank Longo, MD, PhD — Stanford University and PharmatrophiX
1:10 – 1:15

Session Overview

Frank Longo, MD, PhD — Stanford University and PharmatrophiX

1:15 – 1:35

Models for Technology Translation: Innovative Incubator Models

Guy Seabrook, PhD — Johnson & Johnson Innovation

1:35 – 1:45 Q&A
1:45 – 2:05

Intellectual Property Strategies: What and When to File for Patent Protection
Leslie Meyer-Leon, PhD, JD
— IP Legal Strategies Group PC

2:05 – 2:15 Q&A
2:15 – 2:35 A New Paradigm for Translational Research
James Schaeffer, PhD — California Institute for Biomedical Research (Calibr)
2:35 – 2:45 Q&A
2:45 – 3:05 Exhibitor Session and Break
3:05 -3:15 Developing a Biotechnology Company Out of Academia 
Frank Longo, MD, PhD
— Stanford University & PharmatrophiX 
3:15 – 4:00 Panel Discussion: Novel Opportunities for Identifying a Development Partner

MODERATOR: Frank Longo, MD, PhD — Stanford University & PharmatrophiX 

Mark Allegretta, PhD — National Multiple Sclerosis Society 

Michela Gallagher, PhD — AgeneBio  

Leslie Meyer-Leon, PhD, JD — IP Legal Strategies Group PC

James Schaeffer, PhD — California Institute for Biomedical Research (Calibr)

Guy Seabrook, PhD — Johnson & Johnson Innovation 

4:00 – 4:15pm

Closing Remarks

Howard Fillit, MD, Alzheimer's Drug Discovery Foundation